Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
종목 코드 GCTK
회사 이름GlucoTrack Inc
상장일Apr 09, 2013
설립일2010
CEOMr. Paul V. Goode, Ph.D.
직원 수11
유형Ordinary Share
회계 연도 종료Apr 09
주소301 Rt 17 North
도시RUTHERFORD
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호07070
전화197286757878
웹사이트
종목 코드 GCTK
상장일Apr 09, 2013
설립일2010
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음